Indiana Seed Fund II Launches
Indiana-based BioCrossroads has launched an $8.25m early-stage capital fund focused on identifying, creating and developing life sciences companies.
A follow-on to a $6m first fund, Indiana Seed Fund II will invest an average of $500k in early-stage biotechnology, pharmaceutical, medical device, diagnostic, ag-biotech and health information technology products and platforms.
It will be managed by BioCrossroads’ professional team.
The fund is a result of a public-private collaboration of corporate, university and philanthropic investors including:
- BC Initiative (BioCrossroads’ for-profit/investment entity),
- Eli Lilly and Company,
- the Richard M. Fairbanks Foundation, Inc.,
- Indiana University Research and Technology Corporation,
- Purdue University,
- the University of Notre Dame, and